Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
School of Medicine, University of St Andrews, St Andrews, KY16 9TF, UK.
World J Urol. 2018 Dec;36(12):1913-1926. doi: 10.1007/s00345-018-2447-8. Epub 2018 Aug 19.
Pathological parameters assessed on biopsies and resection specimens have a pivotal role in the diagnosis, prognosis and management of patients with renal cell carcinoma (RCC).
A non-systematic literature search was performed, updated to January 2018, to identify key standards and controversies in the pathological classification, grading and staging of RCC.
Although most RCCs exhibit characteristic morphology that enables easy categorisation, RCCs show considerable morphological heterogeneity and it is not uncommon for there to be difficulty in assigning a tumour type, especially with rarer tumour subtypes. The differentiation between benign and malignant oncocytic tumours remains a particular challenge. The development of additional immunohistochemical and molecular tests is needed to facilitate tumour typing, because of the prognostic and therapeutic implications, and to enable more reliable identification of poorly differentiated metastatic tumours as being of renal origin. Any new tests need to be applicable to small biopsy samples, to overcome the heterogeneity of renal tumours. There is also a need to facilitate identification of tumour types that have genetic implications, to allow referral and management at specialist centres. Digital pathology has a potential role in such referral practice.
Much has been done to standardise pathological assessment of renal cell carcinomas in recent years, but there still remain areas of difficulty in classification and grading of these heterogeneous tumours.
活检和切除标本的病理参数在肾细胞癌(RCC)的诊断、预后和治疗管理中具有关键作用。
进行了非系统性文献检索,更新至 2018 年 1 月,以确定 RCC 的病理分类、分级和分期的关键标准和争议。
虽然大多数 RCC 具有易于分类的特征形态,但 RCC 表现出相当大的形态异质性,并且很难确定肿瘤类型并不罕见,尤其是对于较罕见的肿瘤亚型。良性和恶性嗜酸细胞瘤之间的区分仍然是一个特别的挑战。由于预后和治疗意义,需要开发额外的免疫组织化学和分子测试来促进肿瘤分型,并能够更可靠地识别作为肾来源的低分化转移性肿瘤。任何新的测试都需要适用于小的活检样本,以克服肾肿瘤的异质性。还需要促进鉴定具有遗传意义的肿瘤类型,以便在专科中心进行转诊和管理。数字病理学在这种转诊实践中具有潜在的作用。
近年来,在标准化肾细胞癌的病理评估方面已经取得了很大进展,但在这些异质性肿瘤的分类和分级方面仍存在困难。